Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...

Currently, five PARP inhibitor drugs are running in clinical trials for approval. All have shown proof of concept success in germline BRCA mutation carriers. Furthermore, several combinations with ...

Even with an FDA nod covering all HRR mutations, PARP inhibitors like Talzenna are known to work best in the subtype of BRCA mutations. In TALAPRO-2, patients with no BRCA alterations—as ...

Studies show that some drug therapies may be more effective in treating BRCA-related and other genetic ... with potential include expanded use of PARP inhibitors and targeting androgen (the ...

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients.

For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with ...

Jen was eligible for an effective new class of oral medication known as PARP inhibitors called Olaparib. “It’s only been in the last handful of years that this group of patients with the BRCA ...

Germline BRCA 1 and BRCA 2 test results were available ... potentially limiting their responsiveness to PARP [inhibitor]-based therapies," write the authors. They add, "CDK12 mutations, previously ...

Germline BRCA 1 and BRCA 2 test results were available ... potentially limiting their responsiveness to PARP [inhibitor]-based therapies," write the authors. They add: "CDK12 mutations, previously ...

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination ... the HRR-mutated population was observed in patients in both BRCA and non-BRCA gene alterations. Dr. Karim Fizazi, Institut ...